|Brand name(s), other common name(s)||Arzerra®|
|Drug type||Monoclonal antibody|
|How the drug is given||Intravenously (IV)|
Ofatumumab is FDA approved to treat people who have chronic lymphocytic leukemia (CLL) refractory to fludarabine and alemtuzumab. It is also approved in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL), for whom fludarabine-based therapy is considered inappropriate.
Side effects needing medical attention:Fever; cough; diarrhea; rash; neutropenia (abnormally low white blood count); fatigue; pneumonia; anemia; trouble breathing; nausea; infusion reactions; and upper respiratory tract infection.
In patients with prior hepatitis B (HBV) infection, HBV reactivation may occur when the body's immune system is impaired.